{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:44:27Z","timestamp":1751449467449,"version":"3.41.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.2169\/internalmedicine.4377-24","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T22:11:25Z","timestamp":1729807885000},"page":"1706-1711","source":"Crossref","is-referenced-by-count":1,"title":["Renal Pelvic Cancer with Multiple Lung Metastases in a Patient with Polycystic Kidney Disease, Initially Diagnosed as Non-small Cell Lung Cancer: An Autopsy Case Report"],"prefix":"10.2169","volume":"64","author":[{"given":"Chieri","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Tone","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Gochi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University School of Medicine Kashiwa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Jikei University School of Medicine Kashiwa Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[{"name":"Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers 4: 50, 2018.","DOI":"10.1038\/s41572-018-0047-y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gall EC, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet 393: 919-935, 2019.","DOI":"10.1016\/S0140-6736(18)32782-X"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007.","DOI":"10.1016\/S0140-6736(07)60601-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yu TM, Chuang YW, Yu MC, et al. Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol 17: 1419-1425, 2016.","DOI":"10.1016\/S1470-2045(16)30250-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kitchlu A, Reid J, Jeyakumar N, et al. Cancer risk and mortality in patients with kidney disease: a population-based cohort study. Am J Kidney Dis 80: 436-448.e1, 2022.","DOI":"10.1053\/j.ajkd.2022.02.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rosales BM, De La Mata N, Vajdic CM, Kelly PJ, Wyburn K, Webster AC. Cancer mortality in people receiving dialysis for kidney failure: an Australian and New Zealand cohort study, 1980-2013. Am J Kidney Dis 80: 449-461, 2022.","DOI":"10.1053\/j.ajkd.2022.03.010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Huh H, Jo HA, Yi Y, et al. Xp11.2 translocation renal cell carcinoma in the autosomal dominant polycystic kidney disease patient with preserved renal function. Korean J Intern Med 32: 1108-1111, 2017.","DOI":"10.3904\/kjim.2014.133"},{"key":"8","unstructured":"8. Ma SK, Kim SS, Kim SW. Renal papillary adenoma in autosomal dominant polycystic kidney disease. Iran J Kidney Dis 7: 439, 2013."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 22 (Suppl 2): S96-S118, 2009.","DOI":"10.1038\/modpathol.2009.26"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zeile M, Andreou D, Poellinger A, Tunn PU, Dudeck O. Identification of the primary tumour with the help of diffusion-weighted MRI in a patient with autosomal dominant polycystic kidney disease and metastatic renal cell carcinoma. Br J Radiol 84: e142-e145, 2011.","DOI":"10.1259\/bjr\/32867810"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pijl JP, Kwee TC, Slart R, Glaudemans AWJM. FDG-PET\/CT for diagnosis of cyst infection in autosomal dominant polycystic kidney disease. Clin Transl Imaging 6: 61-67, 2018.","DOI":"10.1007\/s40336-017-0261-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bellmunt J, de Wit R, Vaughn DJ, et al.; the KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376: 1015-1026, 2017.","DOI":"10.1056\/NEJMoa1613683"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Balar AV, Galsky MD, Rosenberg JE, et al.; the IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389: 67-76, 2017.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18: 1483-1492, 2017.","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsubara N, de Wit R, Balar AV, et al. Pembrolizumab with or without lenvatinib as first-line therapy for patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind trial. Eur Urol 85: 229-238, 2024.","DOI":"10.1016\/j.eururo.2023.08.012"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387: 1540-1550, 2016.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J 14: 2012-2022, 2021.","DOI":"10.1093\/ckj\/sfab090"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50: 2017.","DOI":"10.1183\/13993003.00050-2017"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 563: 579-583, 2018.","DOI":"10.1038\/s41586-018-0703-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tian F, Liu D, Wei N, et al. Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning. Nat Med 30: 1309-1319, 2024.","DOI":"10.1038\/s41591-024-02915-w"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_4377-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:39:10Z","timestamp":1749271150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/11\/64_4377-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4377-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"4377-24"}}